Education
About Us
Working with TipRanks
Follow Us
Carisma Therapeutics (CARM)
NASDAQ:CARM
CARM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.38 - $2.60
Previous CloseN/A
Volume72.54K
Average Volume (3M)134.83K
Market Cap
$17.27M
Enterprise Value$17.26M
Total Cash (Recent Filing)$50.42M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Apr 08, 2025EPS Estimate
-0.16Last Dividend Ex-Date
Mar 08, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-1.56
Shares Outstanding41,750,110
10 Day Avg. Volume109,337
30 Day Avg. Volume134,829
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.85
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.29
Enterprise Value/Ebitda-0.27
Forecast
1Y Price Target
$6.50Price Target Upside1566.67% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
Carisma Therapeutics News
PremiumCompany Announcements
Carisma Therapeutics Appoints Interim VP of Finance
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company expects its current cash runway to last through the third quarter of 2025, providing a degree of financial stability.
PartnershipsThe expansion of Carisma's partnership with Moderna to include autoimmune programs in addition to oncology work is viewed as a positive signal.
Bears Say
Analyst DowngradeThe rating for Carisma has been downgraded from Buy to Neutral due to a lack of near-term catalysts and a financing overhang.
Program DiscontinuationCarisma announced the discontinuation of their lead HER-2 monocyte program CT-0525 due to lack of strong enrollment and evolving clinical landscape in the treatment of HER2 tumors.
Workforce ReductionThe company's workforce will be reduced by 34% with associated expenses, indicating a significant reorganization effort.
---
Ownership Overview
1.43%
Insiders
4.23% Mutual Funds
3.76% Other Institutional Investors
87.03% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CARM FAQ
What was Carisma Therapeutics’s price range in the past 12 months?
Carisma Therapeutics lowest stock price was $0.38 and its highest was $2.60 in the past 12 months.
What is Carisma Therapeutics’s market cap?
Carisma Therapeutics’s market cap is $17.27M.
When is Carisma Therapeutics’s upcoming earnings report date?
Carisma Therapeutics’s upcoming earnings report date is Apr 08, 2025 which is in 13 days.
How were Carisma Therapeutics’s earnings last quarter?
Carisma Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.315 by $0.005.
Is Carisma Therapeutics overvalued?
According to Wall Street analysts Carisma Therapeutics’s price is currently Undervalued.
Does Carisma Therapeutics pay dividends?
Carisma Therapeutics pays a Notavailable dividend of $0.361 which represents an annual dividend yield of N/A. See more information on Carisma Therapeutics dividends here
What is Carisma Therapeutics’s EPS estimate?
Carisma Therapeutics’s EPS estimate is -0.16.
How many shares outstanding does Carisma Therapeutics have?
Carisma Therapeutics has 41,750,110 shares outstanding.
What happened to Carisma Therapeutics’s price movement after its last earnings report?
Carisma Therapeutics reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.315. Following the earnings report the stock price went down -7.207%.
Which hedge fund is a major shareholder of Carisma Therapeutics?
Currently, no hedge funds are holding shares in CARM
---
Company Description
Carisma Therapeutics
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
---
CARM Stock 12 Month Forecast
Average Price Target
$6.50
▲(1566.67% Upside)
Technical Analysis
Bluebird Bio
―
Fate Therapeutics
―
Adaptimmune Therapeutics
―
Cabaletta Bio
―
Immatics
―
Best Analysts Covering CARM
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-73.82%
reiterated a buy rating 8 months ago
Copying Naureen Quibria's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -73.82% per trade.
---